Zydus Lifesciences Limited · NSE:ZYDUSLIFE
Zydus Lifesciences — Q1 FY27 Earnings Presentation
17 slides from Zydus Lifesciences's earnings presentation, Aug 11, 2026
Slide 1: Exchange filing cover letter for Investor Presentation
August 11, 2026 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Mumbai–400 001 Listing Department Code: ZYDUSLIFE NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai–400 051 Re: Investor Presentation Ref.: Disclosure u
Slide 2: Earnings Presentation: Q1 FY27
Zydus Lifesciences Limited Earnings Presentation: Q1 FY27 11th August 2026
Slide 3: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement • THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF ZYDUS LIFESCIENCES LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general
Slide 4: Q1 FY27: At a Glance
Q1 FY27: At a Glance Revenues from Highlights of Q1 FY27 R&D Operations ❑ Total revenues grew 22% YoY. Rs. 80,170 mn Rs. 6,424 mn ❑ Within Pharmaceutical business, 22% YoY 8% of revenues ➢ India branded formulations sustained strong growth momentum and outpaced the market growth for yet another quar
Slide 5: Key Financial Metrics (1/2)
Key Financial Metrics (1/2) Total Revenues (Rs. mn) Gross Profit (Rs. mn) and Gross Margin % 80,170 72.8% 72.4% 73.2% 74.0 % 72.1% 75,870 65,737 68,645 56,107 57,772 61,232 47,842 50,282 44,327 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Total R&D (Rs. mn) and % t
Slide 6: Key Financial Metrics (2/2)
Key Financial Metrics (2/2) Reported PAT (Rs. mn) Organic Capex (Rs. mn) 14,668 5,852 12,586 12,725 4,911 4,637 10,421 4,020 9,398 3,577 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Q1 FY26 Q2 FY26 Q3 FY26 Q4 FY26 Q1 FY27 Net Debt to EBITDA (x) Net Working Capital* (Rs. mn) 0.70 86,143 81,987 0.49 72,513
Slide 7: India Formulations business
India Formulations business Outperformed IPM across super specialty, chronic and acute segments Highlights for the quarter India Formulations Sales (Rs. mn) Q1 FY27 Revenue ▪ Branded business grew faster than the market with Contribution 17,094 17,528 18,158 20% YoY growth. 15,192 15,926 ▪ Outperfor
Slide 8: North America Formulations business
North America Formulations business Resilient performance on account of base business and branded portfolio Highlights for the quarter North America Formulations Sales (Rs. mn) Q1 FY27 Revenue US Generics Contribution 31,817 30,979 ▪ Base business continued to gain market share driven by 28,043 29,5
Slide 9: International Markets Formulations business
International Markets Formulations business Strong growth on the back of resilient demand across markets Highlights for the quarter IM Formulations Sales (Rs. mn) Q1 FY27 Revenue Contribution ▪ Growth was broad based in both Emerging markets 9,735 (EM) and Europe driven by strong demand and 7,881 8,
Slide 10: Consumer Wellness
Consumer Wellness Strengthening presence across markets Highlights for the quarter Consumer Wellness Sales (Rs. mn) Q1 FY27 Revenue ▪ Domestic business grew 5% y-o-y. Skin & hair care Contribution 14,633 14,292 brands and food & nutrition brands registered 35% and 16% y-o-y growth respectively while
Slide 11: Updates on Innovation and Others
Updates on Innovation and Others NCE Research • The USFDA granted priority review to the New drug Application (NDA) of Saroglitazar Magnesium for the treatment of Primary Biliary Cholangitis (PBC). • Received regulatory approval in India to initiate Phase III clinical trials of Desidustat in patient
Slide 12: Zydus at a Glance
Zydus at a Glance 3rd 10 +$3 R&D Centers Largest generic Co. in US For NCE, APIs, Generics, Vaccines Global Revenues1 bn in terms of prescription3 Biosimilars, Wellness and Med-tech products Among 1st Revenues from Branded Approved product for >55% In ~60% of product Business (Pharmaceutical, Top 3
Slide 13: ESG Performance
ESG PERFORMANCE Climate Change Water (GHG Emissions) Management Net Carbon Neutral by 2035 Net Water Neutral by 2028 50% energy requirements from renewable sources by Creation of water recharge structures in progress 2030 37% of renewable energy in the total energy mix ~68% recycle and reuse of trea
Slide 14: ESG Rankings
ESG RANKINGS 2024 2025 2026 3.3/5 3.2/5 3.9/5 Higher the Better 22% improvement over the previous year’s score of Zydus Lifesciences has 3.2 remained a constituent of the FTSE4Good Index 18% higher than the pharmaceutical subsector average of 3.3 Series for the third consecutive year (2024– 44% high
Slide 15: Consolidated Financial Performance (reported)
Consolidated Financial Performance (reported) Q1 Q1 YoY Q4 QoQ Rs. mn FY27 FY26 gr. FY26 gr. Total Income from Ops. 80,170 65,737 22.0% 75,870 5.7% Gross Contribution (GC) 57,772 47,842 20.8% 56,107 3.0% Gross Margin % 72.1% 72.8% 74.0% Employee benefits expenses* 12,491 9,024 38.4% 11,298 10.6% R&D
Slide 16: Details of Exchange Rate Fluctuations
Details of Exchange Rate Fluctuations Q1 Q1 YoY Rs. mn FY27 FY26 gr. % A. On operating transactions (above EBITDA line) -577 -500 15.4% a. Included in COGS -8 71 -111% b. Part of other operating expenses (shown separately) -569 -571 0% Total Exchange Rate Fluctuations ('+' = loss, '-' = gain) -577 -
Slide 17: Thank you
Thank you For any queries, please contact Arvind Bothra Arvind.Bothra@zyduslife.com +91-79-48040969 Registered Office: For more information, please visit: Zydus Corporate Park, Scheme No. 63, Survey No. 536, www.zyduslife.com Khoraj (Gandhinagar), Nr. Vaishnodevi Circle, Sarkhej-Gandhinagar Highway,